Current Appointments & Affiliations
Associate Professor of Medicine
·
2024 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
An indirect comparison of zanubrutinib vs acalabrutinib plus venetoclax in patients with treatment-naive CLL.
Journal Article Blood Adv · April 28, 2026 In the phase 3 randomized SEQUOIA study (NCT03336333), zanubrutinib (arm A) demonstrated superior progression-free survival (PFS) compared with bendamustine-rituximab (BR; arm B) in patients with treatment-naive chronic lymphocytic leukemia/small lymphocyt ... Full text Link to item CiteRetreatment with venetoclax and rituximab following disease progression while off therapy in patients with chronic lymphocytic leukemia.
Journal Article Hemasphere · December 2025 Full text Link to item CiteRefitting fitness in CLL.
Journal Article Blood · November 13, 2025 Full text Link to item CiteRecent Grants
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
Clinical TrialPrincipal Investigator · Awarded by Celgene Corporation · 2019 - 2031A Single-arm, Phase 2, Open-label, Multicenter Study to Evaluate NX-5948 in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Previously Exposed to a Bruton?s Tyrosine Kinase Inhibitor (BTKi
Clinical TrialPrincipal Investigator · Awarded by Nurix Therapeutics, Inc. · 2026 - 2031The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2025 - 2031View All Grants
Education
Duke University, School of Medicine ·
2007
M.D.